← All companies
$2.19
−3.95% (−$0.09) on the day
Close Nov 13, 2026
Market cap
$95.6M
1 month
−19.19%
52-week range
$1.62–$5.06
Last month
Why we cover it
Pursuing FDA approval of NRX-100, a preservative-free IV ketamine for severe depression, including patients with suicidal thoughts. The FDA has said it doesn't need to run new clinical trials for its application.
Financials
| Cash & equivalents | $26.7M | as of Jun 30, 2026 · 10-Q |
| Revenue | $1.10M | quarter ended Jun 30, 2026 · 10-Q |
| Research & development | $2.12M | quarter ended Jun 30, 2026 · 10-Q |
| Net income (loss) | −$16.5M | quarter ended Jun 30, 2026 · 10-Q |
From the company's SEC filings. See all filings ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| NRX-100 — Preservative-Free IV Ketamine for Severe Depression | Ketamine | NDA planned; FDA has waived the need for new clinical trials |
Patents Patent tracker
| Holder | Compounds | Granted | Pending | Expire |
|---|---|---|---|---|
| NRx Pharmaceuticals, Inc. | Ketamine | 0 | 1 | 2045 |
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.